Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 26;15(10):1856-1864.
doi: 10.1093/ckj/sfac169. eCollection 2022 Oct.

Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study

Borja Quiroga  1 , María José Soler  2   3 , Alberto Ortiz  3   4 , Carlos Jesús Jaravaca Mantecón  5 , Nathasha Nava Pérez  5 , Marta Serra Martín  6 , Yurika Sato  6 , Antonio José Marin Franco  7 , Diana Flor Pazmiño Zambrano  7 , Rafael Lucena Valverde  8 , Mayra Ortega Diaz  8 , Carmen Calderón González  9 , Juan Manuel Cazorla López  10 , Mónica Pereira  4 , Emilio González Parra  4 , Ana Sánchez Horrillo  1 , Carmen Sánchez González  1 , Néstor Toapanta  2 , Secundino Cigarrán Guldris  11 , Rosa Sánchez Hernández  12 , Soledad Pizarro Sánchez  13 , María Muñiz Rincón  14 , Nuria Garcia-Fernández  15 , Natalia Blanco Castro  16 , Rocío Collantes Mateo  17 , Manuel Augusto Quiroz Morales  18 , Beatriz Escamilla-Cabrera  19 , Isabel Berdud Godoy  20 , Beatriz Gil-Casares Casanova  21 , Alba Leyva  22 , José Rojas  22 , Ron T Gansevoort  23 , Patricia de Sequera  3   8 ; SENCOVAC collaborative network
Collaborators, Affiliations

Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study

Borja Quiroga et al. Clin Kidney J. .

Abstract

Background: Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose.

Methods: This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed.

Results: A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P < .001).

Conclusions: In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.

Keywords: COVID-19; SARS-CoV-2; booster; hemodialysis; vaccination.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
FIGURE 1:
FIGURE 1:
Flow chart.
FIGURE 2:
FIGURE 2:
Anti-Spike antibodies 6 and 9 months after the initial SARS-CoV-2 vaccination among hemodialysis patients that had received a booster dose: without a booster dose before the 6th month assessment (late booster, left) and with a booster dose before the 6th month assessment (early booster, right).
FIGURE 3:
FIGURE 3:
Humoral response among SARS-CoV-2-vaccinated hemodialysis patients that had received a booster dose: without a booster dose before the 6th month assessment (late booster, left) and with a booster dose before the 6th month assessment (early booster, right).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sánchez-Alvarez E, Macía M, de Sequera Ortiz P.. Kidney360 2020;1:1254–8. - PMC - PubMed
    1. Andrews N, Tessier E, Stowe Jet al. . Duration of protection against mild and severe disease by COVID-19 vaccines. N Engl J Med 2022;386:340–50. - PMC - PubMed
    1. Quiroga B, Soler MJ, Ortiz Aet al. . Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study. Nephrol Dialysis Transplant 2022;37:994–9(in press). - PMC - PubMed
    1. Dulovic A, Strengert M, Ramos GMet al. . Diminishing immune responses against variants of concern in dialysis patients 4 months after SARS-CoV-2 mRNA vaccination. Emerg Infect Dis 2022;28:743–50. - PMC - PubMed
    1. Federico M. Biological and immune responses to current Anti-SARS-cov-2 mRNA vaccines beyond anti-spike antibody production. J Immunol Res 2022; 2022(in press). Published online 14 May 2022. doi: 10.1155/2022/4028577. - PMC - PubMed